Residency · Residency · Dermatology
Fixed Drug Eruption and Drug-Induced Hyperpigmentation
Introduction
Fixed drug eruption (FDE) and drug-induced hyperpigmentation are common cutaneous adverse drug reactions that are frequently underrecognized. FDE recurs at the same anatomic site with each drug re-exposure, while drug-induced hyperpigmentation involves widespread or localized pigmentary changes from various medications. Both conditions require accurate identification of the causative agent for management and prevention.
Fixed Drug Eruption
Epidemiology
Fixed drug eruption accounts for approximately 10% of all cutaneous drug reactions. It can occur at any age with a slight male predominance and is more clinically apparent in patients with darker skin tones due to prominent post-inflammatory hyperpigmentation.
Pathogenesis
FDE is a type IVc delayed hypersensitivity reaction mediated by resident, tissue-fixed CD8+ effector memory T cells (TRM cells). On initial drug exposure, CD8+ T cells are activated and migrate to specific skin sites where they become intraepidermal resident memory T cells expressing CD69 and CD103. Upon re-exposure, these TRM cells rapidly produce IFN-gamma, TNF-alpha, and cytotoxic mediators (granulysin, perforin, granzyme B), causing localized keratinocyte apoptosis. This mechanism explains the hallmark site-specific recurrence: the TRM cells persist at the original site indefinitely. With repeated episodes, additional sites may be recruited, leading to generalized FDE.
Common Culprit Drugs
TMP-SMX (trimethoprim-sulfamethoxazole) is the most common cause worldwide. Other frequent culprits include NSAIDs (ibuprofen, naproxen, piroxicam, aspirin), tetracyclines (doxycycline, minocycline), acetaminophen/paracetamol, barbiturates and phenytoin, pseudoephedrine and other sympathomimetics, metronidazole, and fluconazole. The latency is characteristically very short on re-exposure (30 minutes to 8 hours), though first exposure may take 1 to 2 weeks.
Clinical Features
FDE presents as solitary or few well-demarcated, round-to-oval, dusky red-to-violaceous patches or plaques. Central vesiculation or bulla may develop in severe cases. Burning or pain is more common than pruritus. Predilection sites include the lips, genitalia (especially the glans penis), hands, feet, and trunk. Genital involvement is particularly common and may be the sole manifestation. Post-inflammatory hyperpigmentation is characteristic, leaving a slate-gray or brown-black residual macule that persists for months to years after resolution and serves as the most important clinical clue. The condition recurs at the same site(s) with each re-exposure, though new sites may be recruited over time. Generalized bullous FDE is a rare variant with widespread bullous lesions that can mimic SJS/TEN, though it is distinguished by a history of prior localized episodes at the same sites and lack of mucosal involvement.
Diagnosis
The diagnosis is clinical, based on characteristic morphology, fixed site recurrence, and temporal correlation with drug exposure. Residual hyperpigmentation between episodes is the key diagnostic clue. Histopathology shows interface dermatitis with necrotic keratinocytes, a dense dermal infiltrate of lymphocytes and neutrophils, and melanin incontinence in the upper dermis; eosinophils may be present. Immunohistochemistry reveals CD8+ TRM cells (CD69+, CD103+) in the epidermis at the lesion site. An oral provocation test is the gold standard for confirming the culprit drug, performed in a controlled setting with the suspected drug, which re-activates the fixed site within hours. Patch testing at the lesion site is positive in approximately 40 to 50% of cases.
Management
The only definitive management is to identify and permanently avoid the culprit drug. Acute treatment involves potent topical corticosteroids for active lesions and cool compresses for bullous lesions. Post-inflammatory hyperpigmentation fades slowly over months to years; topical hydroquinone, azelaic acid, or retinoids may be used but efficacy is limited. The specific drug and reaction type should be clearly documented in the medical record, and patients should be counseled regarding cross-reactivity with structurally related drugs.
<image>Clinical photographs of fixed drug eruption showing: an acute dusky violaceous round plaque with central bulla on the lip, the same site reactivated on drug re-exposure, and residual slate-gray post-inflammatory hyperpigmentation during the quiescent phase between exposures</image>
Drug-Induced Hyperpigmentation
Overview
Drug-induced hyperpigmentation accounts for 10 to 20% of all acquired hyperpigmentation cases. The mechanisms vary by drug class and include melanin overproduction, drug or drug-metabolite deposition in the skin, post-inflammatory changes, and iron deposition. It may affect the skin, mucous membranes, nails, eyes, and internal organs. The condition is often underrecognized because onset is insidious and may not be temporally linked to drug initiation.
Mechanisms of Drug-Induced Pigmentation
Five primary mechanisms are recognized. First, increased melanin synthesis occurs when drugs stimulate melanocytes, as seen with ACTH analogs and oral contraceptives. Second, drug or metabolite deposition occurs when the drug or its breakdown products accumulate in the dermis, as with minocycline, amiodarone, and clofazimine. Third, iron deposition results from drug-induced purpura or hemosiderin deposition, as in minocycline type III. Fourth, post-inflammatory hyperpigmentation develops secondary to drug-induced inflammation, as in FDE. Fifth, phototoxic pigmentation results from the interaction of drug and UV exposure, as with amiodarone and psoralens.
Specific Drug-Induced Pigmentation Patterns
Minocycline
Minocycline produces three distinct types of pigmentation. Type I is blue-gray discoloration in areas of prior scarring or inflammation (such as acne scars), caused by iron-containing pigment complexes. Type II is blue-gray discoloration of previously normal skin, particularly the shins, caused by iron-containing granules in macrophages. Type III is diffuse muddy brown discoloration in sun-exposed areas from increased melanin production. All types may persist for months to years after drug discontinuation, and Types I and II may be permanent. Histopathology shows brown-black granules in the dermis that are positive for Fontana-Masson (melanin) and Perls Prussian blue (iron) staining. QS Nd:YAG laser (1064 nm) can improve minocycline pigmentation.
Amiodarone
Amiodarone causes blue-gray to slate-gray discoloration in sun-exposed areas (face, hands), affecting up to 75% of patients on chronic therapy (typically more than 4 months at doses above 400 mg/day). The mechanism involves a phototoxic reaction leading to lipofuscin-like and melanin-lipid complex deposition in the dermis. Resolution after drug discontinuation is very slow (months to years) due to the extremely long half-life of 40 to 55 days.
Antimalarials (Hydroxychloroquine, Chloroquine)
Antimalarials produce blue-gray to black pigmentation of the skin, particularly the pretibial area, palate, and nail beds. They also cause yellow-brown retinal pigment deposition (macular toxicity requiring ophthalmologic screening). This is more common with chloroquine than hydroxychloroquine and is partially reversible upon discontinuation.
Chemotherapy Agents
Bleomycin causes flagellate (linear, whip-like) hyperpigmentation along lines of scratching or pressure. Cyclophosphamide produces diffuse or nail hyperpigmentation. 5-Fluorouracil causes hyperpigmentation in sun-exposed areas and over veins used for infusion ("serpentine supravenous hyperpigmentation"). Doxorubicin produces hyperpigmentation of nails, skin folds, and oral mucosa.
Heavy Metals
Silver (argyria) causes permanent blue-gray skin discoloration from silver granule deposition in the dermis. Gold (chrysiasis) produces blue-gray pigmentation in photo-exposed areas from parenteral gold therapy. Bismuth causes blue-black pigmentation of the gingival margin (bismuth line).
| Drug | Pigmentation Pattern | Color | Location | Mechanism | Reversibility |
|---|---|---|---|---|---|
| Minocycline Type I | Blue-gray at scars/inflammation | Blue-gray | Acne scars | Iron-pigment complexes | Slow; may be permanent |
| Minocycline Type II | Blue-gray on normal skin | Blue-gray | Shins | Iron granules in macrophages | Slow; may be permanent |
| Minocycline Type III | Muddy brown | Brown | Sun-exposed | Increased melanin | Usually reversible |
| Amiodarone | Slate-gray | Blue-gray | Sun-exposed (face, hands) | Lipofuscin + melanin-lipid deposition | Very slow (months-years) |
| Hydroxychloroquine | Blue-gray to black | Blue-gray/black | Pretibial, palate, nails | Drug deposition | Partially reversible |
| Bleomycin | Flagellate (linear) | Brown | Lines of scratching/pressure | Direct toxicity | Usually reversible |
| Silver (argyria) | Blue-gray (permanent) | Blue-gray | Diffuse | Silver granule deposition | Permanent |
Psychotropic Medications
Chlorpromazine and other phenothiazines cause blue-gray pigmentation in sun-exposed areas at high doses. Imipramine produces a similar blue-gray pigmentation, particularly photodistributed.
Oral Contraceptives/Hormone Therapy
Estrogen and progesterone stimulate melanogenesis, causing melasma, which is covered in detail in Lecture 55.
<image>Clinical comparison panel of drug-induced hyperpigmentation patterns: minocycline Type I (blue-gray in acne scars), minocycline Type II (blue-gray on shins), amiodarone (slate-gray on sun-exposed face), and bleomycin flagellate hyperpigmentation (linear whip-like streaks on the trunk)</image>
Diagnosis of Drug-Induced Hyperpigmentation
A comprehensive medication review including all current and recent medications, OTC products, supplements, and herbal products is essential. Timeline correlation between pigmentation onset and drug initiation should be established, though this may be months to years later. The distribution pattern provides diagnostic clues: photodistributed pigmentation suggests amiodarone or phenothiazines, pigmentation at sites of inflammation suggests minocycline Type I, and other patterns may be diffuse or nail-specific. Skin biopsy with special stains is informative: Fontana-Masson for melanin deposits, Perls Prussian blue for iron and hemosiderin, and polarized light for birefringent drug deposits. Wood's lamp examination may enhance visualization of pigment depth (epidermal versus dermal).
Management of Drug-Induced Hyperpigmentation
Drug discontinuation or substitution when clinically feasible is the most important step. Sun protection with strict photoprotection prevents worsening of photosensitive types. Time is often the most effective treatment, as many forms gradually improve over months to years after drug cessation. Topical agents such as hydroquinone 4%, azelaic acid 20%, and topical retinoids have limited efficacy for deep dermal pigment. QS laser therapy (Nd:YAG 1064 nm, alexandrite 755 nm) is effective for minocycline and some other deposited pigments, with a test spot recommended. Chemical peels (superficial peels) may help with epidermal melanin but are ineffective for dermal deposits. Some pigmentation, such as argyria and minocycline Types I and II, may be permanent even with treatment.
Key Clinical Pearls
FDE recurs at exactly the same anatomic site with each drug re-exposure, a pathognomonic feature driven by tissue-resident memory T cells that persist indefinitely at the site. Generalized bullous FDE can mimic SJS/TEN, but a history of prior episodes at the same sites, mucosal sparing, and residual hyperpigmentation distinguish it. Genital FDE is extremely common and frequently misdiagnosed as herpes simplex; FDE should always be considered in recurrent genital erosions. Minocycline pigmentation has three distinct clinical patterns with different mechanisms, all of which may coexist in the same patient. Drug-induced hyperpigmentation is often underrecognized because onset is insidious, making a thorough medication review essential in any patient with unexplained acquired pigmentation.
<image>Flowchart for the diagnostic approach to acquired hyperpigmentation showing decision tree: medication review leading to suspected drug-induced causes categorized by photodistributed versus non-photodistributed patterns, with biopsy and special stain recommendations for each category</image>
References
- Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9(4):316-321.
- Rahimi H, Tehranchinia Z. A comprehensive review of cutaneous drug-induced hyperpigmentation. J Clin Aesthet Dermatol. 2020;13(1):32-39.
- Dereure O. Drug-induced skin pigmentation: epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253-263.
- Flowers H, Brodell R, Brents M, Wyatt JP. Fixed drug eruptions: presentation, diagnosis, and management. South Med J. 2014;107(11):724-727.
